“Once-daily intravenous busulfan as myeloablative, reduced-toxicity conditioning regimen: results in young and adult patients with hematological malignant and nonmalignant diseases”, Hematol Meeting Rep, vol. 2, no. 6, Jun. 2009, doi: 10.4081/hmr.v2i6.771.